BIOTECH CATALYST AI SCANNER — October WK 4
BIOSTOCKINFO / CATALYST SCANNER
Scan date 2026-10-18 · 10 featured · 10 watchlist
The tape
The supplied market feed shows XBI at 144.32: −6.2% weekly, −6.4% monthly, −6.4% over three months, +18.8% year to date, and −14.9% below its 52-week high. SPY closed at 763.25: −2.0% weekly, +1.2% monthly, +2.7% over three months, +11.7% year to date, and −2.0% below its high. The decline was market-wide, but biotech suffered a substantially deeper weekly selloff.
The supplied breadth reading shows 35% of 5,528 tracked US small and mid caps above their 20-day average on 2026-10-16. Catalyst-driven names face weak participation rather than broad support from rising smaller companies.
The supplied Treasury feed puts the ten-year yield at 5.10% on 2026-10-16, down 15 basis points weekly but up 56 over three months. Its 52-week range was 3.95%–5.31%.
This week at a glance
| TICKER | CATALYST | DATE | RANK |
|---|---|---|---|
| NRXP | GDUFA, ketamine | Nov 10, 2026 | 88 |
| NKTX | Conference Presentation, NKX019 | Nov 8, 2026 | 86 |
| BDTX | Interim Data, silevertinib | fourth quarter of 2026 | 84 |
| ZURA | Topline Data, tibulizumab | Q4 2026 | 84 |
| SLGL | Topline Data, SGT-610 (patidegib gel, 2%) | late November 2026 | 83 |
| ACRS | Topline Data, bosakitug | Fourth Quarter 2026 | 82 |
| FBIO | Topline Data, Triplex | late 2026 | 81 |
| RZLT | Topline Data, ersodetug | mid-December 2026 | 80 |
| ENTA | Topline Data, EDP-978 | fourth quarter of 2026 | 80 |
| VIR | Topline Data, elebsiran and tobevibart | in the fourth quarter of 2026 | 80 |
Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.
Featured
NRXP — NRx Pharmaceuticals
CATALYST Nov 10, 2026Regulatory | RANK 88 | PRICE $2.60 -22% 20d |
| CAP $113M (43M sh) | CASH $41M ~25 mo | |
The Food and Drug Administration’s preservative-free ketamine ANDA review goal date is Nov 10, 2026. This concerns generic approval, not approval of the separate depression indication or a clinical-trial result.
Company. NRx develops therapeutics based on a glutamate-signaling platform, including preservative-free intravenous ketamine. Its filings distinguish the generic application from a separate NDA targeting suicidal ideation in depression, including bipolar depression, and describe clinic revenue.
Science & competition. Ketamine blocks nerve-cell receptors involved in glutamate signaling. Rivals include Auvelity (Axsome Therapeutics, Approved 2022 for MDD) and Zulresso (Sage Therapeutics, Approved 2019 for postpartum depression in adults). These depression indications differ. Care includes antidepressants, psychotherapy, urgent safety assessment, and higher-level care when needed.
Competition sources
Sources: These highlights do not include all the information needed to use SPRAVATO safely and effectively. See full prescribing information for SPRAVATO. SPRAVATO® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine) · NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting | Mon, 03/16/2026 - 07:00
Why it could work. The company reported no drug-related major deficiencies in first-cycle review. The FDA subsequently reclassified the amendment as minor, narrowing the remaining regulatory work rather than establishing approval.
Why it could fail. Final manufacturing, packaging, or inspection issues can still delay clearance. Approval also leaves a commercial challenge: selling a generic product against inexpensive, established alternatives with constrained pricing power.
Recent development. On October 15, 2026, NRx reported an FDA labeling review letter requesting minor label changes and sample labeling. The ANDA remained under review. This is progress within the featured application, not an approval or a decision on the separate depression NDA.
NKTX — Nkarta
CATALYST Nov 8, 2026Conference | RANK 86 | PRICE $1.80 -36% 20d |
| CAP $129M (72M sh) | CASH $215M ~28 mo | |
Nkarta expects preliminary Phase 1/2 NKX019 results in idiopathic inflammatory myopathy on Nov 8, 2026. The presentation tests whether donor-derived immune cells show usable safety and early activity in autoimmune muscle disease.
Company. Nkarta develops cell therapies, with NKX019 targeting autoimmune diseases through donor-derived natural killer cells. The selected myopathy study forms part of that autoimmune program; company disclosures describe funding for continued development and an available share-sale facility.
Science & competition. Engineered natural killer cells target CD19 to remove disease-driving B cells. Rivals include brepocitinib (Priovant Therapeutics, FDA-approved, 2026 for adult dermatomyositis) and anifrolumab (AstraZeneca, Phase 3 for polymyositis and dermatomyositis). Standard care uses glucocorticoids and steroid-sparing immunosuppressants. The rival indications cover specific myopathy subtypes.
Competition sources
Sources: FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults · Study Details | NCT06455449 | A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | ClinicalTrials.gov · Study Details | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | ClinicalTrials.gov · BLA 125062-674_07-15-2021_Memo_Committee Memo_Clinical
Why it could work. Batch manufacturing offers an off-the-shelf product without individualized cell production. The biological opportunity is substantial B-cell depletion alongside early clinical improvement, without severe immune toxicity.
Why it could fail. Donor-derived cells may disappear before clearing disease-driving B cells in tissues. Short persistence would leave transient biological activity without sustained improvement in muscle disease.
Market context. This is preliminary evidence from an open-label study, not a controlled efficacy verdict. The supplied disclosures do not state the presentation’s sample size or primary endpoint. Cell persistence, safety, and clinical activity therefore need separate assessment; a depletion signal alone does not establish durable benefit.
BDTX — Black Diamond Therapeutics
CATALYST fourth quarter of 2026Data readout | RANK 84 | PRICE $1.72 -12% 20d |
| CAP $99M (57M sh) | CASH $101M ~37 mo | |
Silevertinib’s frontline Phase 2 lung-cancer update is expected in the fourth quarter of 2026 (company's words; quarter-level precision). Updated durability and FDA feedback will clarify the development path in non-classical epidermal growth factor receptor-mutant non-small cell lung cancer.
Company. Black Diamond develops therapies targeting families of cancer-driving mutations. Silevertinib is its investigational oral, brain-penetrant inhibitor for non-classical receptor mutations; the company is seeking FDA feedback on pivotal development alongside further frontline clinical follow-up.
Science & competition. Silevertinib permanently binds a mutated growth receptor to block tumor signaling, including in the brain. Rivals include afatinib (Boehringer Ingelheim, FDA-approved) and firmonertinib (Allist Pharmaceuticals, Phase 3). Standard treatment is mutation-specific; afatinib is approved for selected uncommon sensitizing variants, not the entire non-classical mutation group.
Competition sources
Sources: These highlights do not include all the information needed to use AFATINIB TABLETS safely and effectively. See full prescribing information for AFATINIB TABLETS. AFATINIB tablets, for oral use Initial U.S. Approval: 2013 · ALPACCA: Phase 3 trial of firmonertinib vs investigator’s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006). | Journal of Clinical Oncology · Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
Why it could work. Earlier reporting showed a 60% overall response rate. Brain activity and continuing responses support further development, provided longer follow-up preserves the initial durability signal.
Why it could fail. Small-cohort durability estimates can weaken with follow-up. Cumulative toxicity or FDA requirements for a lengthy randomized pivotal trial would increase the development burden and capital requirements.
Market context. The clinical update and regulatory-path update answer different questions. Sustained responses do not establish an accelerated approval route. Conversely, a clear pivotal design does not remove uncertainty around long-term tolerability. The unresolved issue is how much additional evidence the FDA requires before a submission.
ZURA — Zura Bio
CATALYST Q4 2026Data readout | RANK 84 | PRICE $3.88 -13% 20d |
| CAP $372M (96M sh) | CASH $182M ~28 mo | |
TibuSHIELD Phase 2 tibulizumab topline results in hidradenitis suppurativa are expected in Q4 2026 (company's words; quarter-level precision). The placebo-controlled study tests whether the dual-target antibody reduces disease activity with acceptable safety.
Company. Zura is a clinical-stage immunology company developing antibodies for autoimmune and inflammatory diseases. Lead candidate tibulizumab is being tested in TibuSHIELD for hidradenitis suppurativa; the company completed enrollment and raised equity to support planned development.
Science & competition. Tibulizumab blocks interleukin-17A and B-cell activating factor, targeting inflammatory signaling and B-cell survival. Rivals include adalimumab (AbbVie; biosimilar sponsors, FDA-approved for HS in 2015) and bimekizumab (UCB, FDA-approved for adults in 2024). Care combines medical treatment, antibiotics, appropriate biologics, and surgery for persistent tunnels or scarring.
Competition sources
Why it could work. The dual mechanism addresses inflammatory signaling and B-cell activity together. TibuSHIELD randomized 247 participants, providing a controlled test of whether that biological rationale produces meaningful clinical benefit.
Why it could fail. Additional B-cell inhibition may add infection risk without sufficient clinical benefit. Variable placebo responses and fluctuating lesion counts can also erase statistical separation in this disease.
Market context. Enrollment is complete, but the supplied filings do not specify the primary endpoint, dosing arms, or analysis population. Those details matter when interpreting topline claims. A positive result needs its actual endpoint and safety context; the mechanism alone does not establish the contribution of each target.
SLGL — Sol-Gel Technologies
CATALYST late November 2026Data readout | RANK 83 | PRICE $64.25 +7% 20d |
| CAP $210M (3M sh) | CASH $49M (burn n/a) | |
SGT-610-01 Phase 3 Gorlin syndrome results are expected in late November 2026 (company's words; month-level precision), with ODD, BTD. The pivotal study tests whether topical patidegib prevents new facial basal cell carcinomas.
Company. Sol-Gel develops dermatology treatments, including topical patidegib for preventing new skin cancers in adults with Gorlin syndrome. Its pivotal study has completed patient follow-up; database lock and statistical analysis precede the expected topline release.
Science & competition. Patidegib blocks hedgehog signaling, a pathway that drives tumor growth, through a gel applied to the skin. Standard care includes regular dermatologic surveillance and surgical removal of basal cell carcinomas. No drug is specifically FDA-approved for Gorlin syndrome; prevention is distinct from treating an existing lesion.
Competition sources
Sources: https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/ex99-1.htm?utm_source=openai · Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome | Sol-Gel Technologies Ltd
Why it could work. The company reported 102 study completers. Strong retention preserves evaluable follow-up for the prevention endpoint, although it does not establish efficacy or reveal outcomes by treatment assignment.
Why it could fail. The gel may not reach the relevant skin layers at effective concentrations. Failure to reduce new facial tumors versus vehicle would undermine the pivotal program despite completed follow-up.
Market context. The primary endpoint counts new facial tumors after treatment; a secondary endpoint counts new surgically eligible tumors. The latter addresses whether prevention translates into fewer lesions requiring operations. Treatment assignments remain blinded, so retention cannot identify which arm benefited or establish comparative tolerability.
ACRS — Aclaris Therapeutics
CATALYST Fourth Quarter 2026Data readout | RANK 82 | PRICE $3.28 -40% 20d |
| CAP $483M (147M sh) | CASH $192M ~37 mo | |
Bosakitug’s Phase 2 atopic dermatitis topline results are expected in Fourth Quarter 2026 (company's words; quarter-level precision). The randomized trial tests whether blocking an upstream inflammatory signal improves eczema relative to placebo.
Company. Aclaris develops treatments for immuno-inflammatory diseases. Bosakitug is its investigational antibody targeting thymic stromal lymphopoietin, an upstream inflammatory protein; filings also identify licensing relationships with Lilly and Sun Pharma and financing to support operations.
Science & competition. Bosakitug blocks thymic stromal lymphopoietin before downstream inflammatory pathways activate. Rivals include dupilumab (Regeneron / Sanofi, Approved 2017) and tralokinumab (LEO Pharma, Approved 2021). Standard care starts with skin-barrier care and prescription topical anti-inflammatory treatment, adding targeted biologics or oral enzyme inhibitors for inadequately controlled disease.
Competition sources
Sources: These highlights do not include all the information needed to use DUPIXENT safely and effectively. See full prescribing information for DUPIXENT. DUPIXENT® (dupilumab) injection, for subcutaneous useInitial U.S. Approval: 2017 · Drug Trials Snapshot: CIBINQO | FDA · Drug Trials Snapshots: EBGLYSS | FDA · Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis | Galderma
Why it could work. Upstream blockade offers a rationale for suppressing several inflammatory signals together. The fully enrolled, 109-patient trial provides a placebo-controlled test of skin improvement and symptom relief.
Why it could fail. Established eczema may remain active through downstream pathways despite upstream blockade. Weak separation from placebo would challenge bosakitug’s standalone biological rationale, even if the drug is tolerable.
Market context. The supplied 10-Q specifies the primary endpoint: percentage change in Eczema Area and Severity Index at week 24. Secondary measures include skin-response thresholds and itch. These measures distinguish average improvement from deeper skin clearance and symptom relief; they should not be treated as interchangeable outcomes.
FBIO — Fortress Biotech
CATALYST late 2026Data readout | RANK 81 | PRICE $1.87 -25% 20d |
| CAP $62M (33M sh) | CASH $197M no net burn | |
Triplex Phase 2 topline results in adults with human immunodeficiency virus and cytomegalovirus are expected in late 2026 (company's words; quarter-level precision). The readout tests immune-based control of cytomegalovirus in this specific co-infected population.
Company. Fortress acquires and advances biopharmaceutical assets and reports product revenue, royalties, dividends, and equity holdings. Helocyte develops Triplex, a potential cytomegalovirus vaccine and immunotherapy; the selected co-infection study is fully enrolled and awaits topline results.
Science & competition. Triplex uses a viral vector to stimulate infection-fighting T cells against cytomegalovirus. Rivals include ganciclovir (Syntex/Roche, Approved 1989) and valganciclovir (Roche, Approved 2001). Standard antiviral treatment generally uses these drugs; transplant prevention differs from the featured human immunodeficiency virus co-infection population and may use letermovir.
Competition sources
Sources: Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients | Annual Reviews · Pioneering mRNA technology - Moderna · Review
Why it could work. Stimulating the body’s cellular immune response offers a route to sustained viral control. Clear immune activity alongside reduced cytomegalovirus activity would establish biological proof of concept in this population.
Why it could fail. Sparse disclosure of study size, controls, and endpoints limits interpretation. An immune response without meaningful viral control would leave the therapeutic case unresolved rather than establish clinical benefit.
Recent development. Fortress reported repayment of its remaining credit facility on September 30, 2026. The debt was satisfied, liens released, and agreement terminated. This removes that facility’s debt and collateral obligations; it does not identify how much consolidated cash is available specifically for Helocyte or Triplex.
RZLT — Rezolute
CATALYST mid-December 2026Data readout | RANK 80 | PRICE $3.58 -7% 20d |
| CAP $346M (97M sh) | CASH $86M ~14 mo | |
Ersodetug’s upLIFT Phase 3 tumor hyperinsulinism results are expected in mid-December 2026 (company's words; month-level precision), with BTD. The study tests whether treatment reduces dependence on continuous intravenous glucose in patients with uncontrolled tumor-related hypoglycemia.
Company. Rezolute develops ersodetug for refractory low blood sugar caused by hyperinsulinism. The selected upLIFT study includes insulinoma and non-islet cell tumors; enrollment is complete, and the company has reported no drug-related safety findings to date.
Science & competition. Ersodetug binds the insulin receptor to block excessive signaling that drives dangerously low blood sugar. Standard care addresses the underlying tumor when feasible and controls hypoglycemia with intravenous glucose and individualized medical therapy. There is no approved drug specifically for tumor hyperinsulinism in the supplied competition assessment.
Competition sources
Sources: REZOLUTE, INC._June 30, 2026
Why it could work. Seven of the first eight participants completely stopped intravenous glucose. That exceeds the trial’s reduction-based response criterion, but the completed cohort must still clear the prespecified statistical threshold.
Why it could fail. Advanced cancer creates substantial competing risk. The initial non-responder died from cancer progression after entering hospice; further deaths, incomplete assessments, or new toxicity could weaken this small study’s result.
Recent development. On October 5, 2026, Rezolute said the FDA recommended requesting a pre-BLA meeting after preliminary review of sunRIZE in congenital hyperinsulinism. That separate indication missed its primary and key secondary endpoints. The recommendation opens regulatory discussion; it does not establish approvability or predict the tumor-HI upLIFT outcome.
Filing flag. One of the first 8 participants died one week after entering hospice, due to cancer progression; the company counts this participant as a non-responder. Ersodetug remains investigational, and safety and efficacy statements have not been approved by a health authority.
ENTA — Enanta Pharmaceuticals
CATALYST fourth quarter of 2026Data readout | RANK 80 | PRICE $11.10 -9% 20d |
| CAP $323M (29M sh) | CASH $201M ~68 mo | |
EDP-978 Phase 1 topline results are expected in the fourth quarter of 2026 (company's words; quarter-level precision). This healthy-volunteer study tests safety and biological activity, not symptom improvement in chronic urticaria patients.
Company. Enanta discovers and develops small-molecule drugs for viral infections and immunological diseases. EDP-978 is an oral, once-daily candidate for chronic urticaria and other mast-cell diseases; its first-in-human program is testing safety, exposure, and biological effects.
Science & competition. EDP-978 blocks KIT, a survival and activation switch for histamine-releasing mast cells. Rivals include omalizumab (Genentech/Novartis, FDA-approved for CSU, 2014) and remibrutinib (Novartis, FDA-approved for CSU, 2025). For chronic spontaneous urticaria, standard care starts with second-generation antihistamines, escalating doses and adding targeted therapy when symptoms persist.
Competition sources
Sources: Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria | Enanta Pharmaceuticals, Inc. · FDALabel · Drug Trials Snapshot: RHAPSIDO | FDA · These highlights do not include all the information needed to use DUPIXENT safely and effectively. See full prescribing information for DUPIXENT. DUPIXENT® (dupilumab) injection, for subcutaneous useInitial U.S. Approval: 2017 · https://www.sec.gov/Archives/edgar/data/744218/000110465926109465/tm2625892d1_ex99-1.htm?utm_source=openai · Review
Why it could work. Once-daily oral dosing offers convenience. A dose-dependent reduction in serum tryptase would support mast-cell suppression and provide a measurable biological signal before trials in patients with chronic urticaria.
Why it could fail. KIT also supports pigment cells and blood-cell production. Toxicity or weak tryptase suppression at tolerated doses would limit advancement, even if oral drug exposure is adequate.
Market context. The study includes single-dose testing, food-effect assessment, and repeated dosing over 14 days. Serum tryptase is a biological marker, not a patient symptom endpoint. A favorable result can support dose selection and further development without demonstrating durable disease control or chronic-treatment safety.
VIR — Vir Biotechnology
CATALYST in the fourth quarter of 2026Data readout | RANK 80 | PRICE $9.96 -6% 20d |
| CAP $1.7B (169M sh) | CASH $949M ~56 mo | |
Elebsiran plus tobevibart Phase 3 ECLIPSE 1 topline results in chronic hepatitis delta are expected in the fourth quarter of 2026 (company's words; quarter-level precision). The registrational readout tests whether the combination’s earlier viral suppression translates into a successful pivotal result.
Company. Vir develops medicines for serious infectious diseases and cancer. Its hepatitis delta program combines Alnylam-licensed elebsiran with tobevibart, administered monthly as separate sequential injections; the company also has oncology programs outside this featured infectious-disease regimen.
Science & competition. Elebsiran silences viral protein production; tobevibart binds viral surface antigens. Rivals include bulevirtide (Gilead Sciences, FDA-approved 2026) and peginterferon lambda-1a (Eiger BioPharmaceuticals, Phase 3 (LIMT-2)). Bulevirtide is the approved hepatitis delta-specific treatment; pegylated interferon alfa may also be considered for eligible patients as part of care.
Competition sources
Sources: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection | FDA · Press Release: EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026 - EIT Pharma, Inc. · Study Details | NCT05070364 | Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV | ClinicalTrials.gov
Why it could work. In Phase 2, 88% of combination recipients had undetectable hepatitis delta viral RNA by intent-to-treat analysis. The company reported no treatment-related serious adverse events or discontinuations.
Why it could fail. Viral rebound, liver-enzyme flares, or weaker pivotal responses would challenge the regimen. Manufacturing and administering two separate injectable products also adds complexity to eventual treatment delivery.
Watchlist
PHAT — Phathom Pharmaceuticals
CATALYST fourth quarter of 2026Data readout | RANK 79 |
| PRICE $6.92 -7% 20d | CAP $560M (81M sh) |
Cash $171M, ~56 mo
VOQUEZNA’s Phase 2 pHalcon-EoE-201 results are expected in the fourth quarter of 2026 (company's words; quarter-level precision). The randomized study enrolled 95 adults with eosinophilic esophagitis and swallowing difficulty, testing the blinded treatment period against placebo. The supplied disclosures do not specify the primary endpoint, limiting interpretation until fuller results arrive.
SVRA — Savara
CATALYST Nov 22, 2026Regulatory | RANK 78 |
| PRICE $4.45 -17% 20d | CAP $914M (206M sh) |
Cash $140M, ~15 mo
ODD FTD BTD Priority ReviewThe MOLBREEVI BLA for autoimmune pulmonary alveolar proteinosis has a PDUFA target action date of Nov 22, 2026. Savara previously reported positive Phase 3 IMPALA-2 topline results; designations include ODD, FTD, BTD, Priority Review. The FDA extended review after information-request responses constituted a major amendment; that unresolved review is the immediate risk.
OCS — Oculis
CATALYST around year-endData readout | RANK 78 |
| PRICE $7.29 -28% 20d | CAP $495M (68M sh) |
Cash $41M, ~7 mo
Licaminlimab’s PREDICT-1 dry-eye results are expected around year-end (company's words; quarter-level precision). Earlier studies showed a greater treatment effect in a specific receptor-genotype subgroup, making prospective confirmation the central test rather than a general dry-eye efficacy claim. The company reported only one-third enrolled in August, leaving trial completion and reporting execution important.
TRVI — Trevi Therapeutics
CATALYST in the fourth quarter of 2026Data readout | RANK 77 |
| PRICE $11.88 -21% 20d | CAP $1.7B (142M sh) |
Cash $303M, ~69 mo
Haduvio’s Phase 2b LAKE sample-size re-estimation is expected in the fourth quarter of 2026 (company's words; quarter-level precision). This is an interim trial-sizing analysis in refractory chronic cough, not topline efficacy; the company will report the outcome once available. Planned spending funds LAKE but excludes a subsequent Phase 3 refractory-cough trial, leaving later development costs outside that plan.
ZBIO — Zenas BioPharma
CATALYST 4Q 2026Data readout | RANK 77 |
| PRICE $24.84 -21% 20d | CAP $1.6B (65M sh) |
Cash $606M, ~32 mo
Filing warningObexelimab’s Phase 2 SunStone lupus results are expected in 4Q 2026 (company's words; quarter-level precision). The randomized, placebo-controlled study will report overall and biomarker-population findings, which inform the potential Phase 3 decision. The timeline moved from an earlier midyear expectation without explanation, and company funding guidance also assumes conditional payments tied to another indication.
Filing flag. The topline timeline changed: on November 12, 2025, Zenas expected results in mid-2026; by May 13, 2026, it expected results in 4Q 2026. The filings do not explain the delay.
SMMT — Summit Therapeutics
CATALYST Nov 14, 2026Regulatory | RANK 76 |
| PRICE $14.63 -18% 20d | CAP $11.7B (798M sh) |
Cash $553M, ~14 mo
financing filed since the cash dateFTD Filing warningIvonescimab plus chemotherapy has a BLA PDUFA goal date of Nov 14, 2026, following prior growth-receptor inhibitor treatment in receptor-mutated non-squamous lung cancer; FTD. Updated HARMONi survival reporting showed consistent hazard ratios across geographic subgroups, with no additional safety signals. Summit’s July financial statements explicitly said existing cash and investments were insufficient for a year of planned operations.
Filing flag. On July 23, 2026, Summit stated that cash and cash equivalents and short-term investments were not sufficient to fund planned operations for at least one year from issuance of its financial statements.
AXSM — Axsome Therapeutics
CATALYST fourth quarter of 2026Data readout | RANK 76 |
| PRICE $157.14 -24% 20d | CAP $8.2B (52M sh) |
Cash $298M, ~50 mo
Filing warningSolriamfetol’s ENGAGE Phase 3 binge-eating disorder results are expected in the fourth quarter of 2026 (company's words; quarter-level precision). The supplied validation evidence describes a randomized, double-blind, placebo-controlled study. Guidance narrowed from broader annual and half-year windows; the primary endpoint and sample size are not specified in the supplied disclosures, leaving the precise efficacy bar unstated.
Filing flag. The expected topline timeline was narrowed from “2026” in filings dated August 4 and November 3, 2025, and “second half of 2026” in filings dated February 23 and May 4, 2026, to “fourth quarter of 2026” on August 10, 2026.
RAPP — Rapport Therapeutics
CATALYST October 2026Data readout | RANK 75 |
| PRICE $27.57 -32% 20d | CAP $1.3B (48M sh) |
Cash $407M, ~51 mo
RAP-219 Phase 2 bipolar-mania results are expected in October 2026 (company's words; month-level precision). Rapport increased target enrollment and modified the statistical analysis plan so the study might provide confirmatory evidence of effectiveness. That possibility is not a regulatory determination; results and an end-of-Phase 2 FDA discussion still govern the proposed pivotal development path.
BNTC — Benitec Biopharma
CATALYST Oct 27–Oct 30, 2026Conference | RANK 75 |
| PRICE $8.11 -26% 20d | CAP $283M (35M sh) |
Cash $174M, ~106 mo
Filing warningBB-301 Phase 1b/2a results for OPMD-related swallowing difficulty are scheduled for Oct 27–Oct 30, 2026, at the European Society of Gene and Cell Therapy congress. Follow-up includes all six first-cohort and three second-cohort patients, extending earlier reported swallowing improvements. The FDA requested additional data before pivotal-design confirmation, now expected in early 2027, leaving the registrational design unresolved.
Filing flag. On October 5, 2026, Benitec said FDA requested additional available data, including from its OPMD Natural History Study, and final pivotal design confirmation moved to 1Q 2027; the company said the pivotal trial remains on track to begin in mid-2027.
SLS — SELLAS Life Sciences
CATALYST Q4 2026Data readout | RANK 74 |
| PRICE $9.98 -13% 20d | CAP $2.0B (202M sh) |
Cash $130M, ~55 mo
Tambiciclib’s Phase 2 newly diagnosed acute myeloid leukemia results are expected in Q4 2026 (company's words; quarter-level precision). SELLAS reported 28 participants enrolled in the planned 80-patient study, including patients identified as becoming refractory early to azacitidine and venetoclax. Earlier response findings came from relapsed or refractory disease and do not establish outcomes in this different frontline population.
The Take
The calendar divides into regulatory execution, pivotal confirmation, and early biological proof. NRXP and SVRA face application reviews; SLGL, RZLT, and VIR face clinical results with direct registrational consequences. NKTX and ENTA instead need evidence that their mechanisms produce usable activity, not just attractive laboratory rationale. The tape argues against treating these groups as interchangeable anticipation trades. Biotech fell harder than the broader market, breadth is weak, and the ten-year yield remains elevated despite its weekly decline. The asymmetry sits in evidence that resolves a defined uncertainty: actual approval, prevention of new tumors, reduced glucose dependence, or replicated viral suppression. BDTX adds another distinction: encouraging follow-up does not settle the FDA development path. ZURA and ACRS need controlled clinical benefit, while TRVI’s sizing analysis cannot substitute for efficacy results. Event labels matter as much as proximity.
How the scanner ranks names, estimates cash and reads dates is explained in the methodology note. Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.
Disclaimer
For information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital.
